Mode
Text Size
Log in / Sign up

New analysis shows finerenone and SGLT2 drugs help lower heart failure hospitalization risks for patients with preserved ejection fraction

Share
New analysis shows finerenone and SGLT2 drugs help lower heart failure hospitalization risks for pat…
Photo by National Cancer Institute / Unsplash

A major study looked at many different heart medicines for patients with heart failure where the heart muscle squeezes well. This included over 65,000 people taking drugs like finerenone, SGLT2 inhibitors, and others. The goal was to see which treatments worked best for keeping people out of the hospital.

The results showed that finerenone and SGLT2 inhibitors helped lower the chance of needing the hospital for heart problems. Patients taking these drugs had fewer bad heart events compared to those taking placebo or other standard drugs. This means these new medicines could be very helpful for many patients.

However, the study also found some risks. Some drugs had higher chances of side effects or kidney issues. The researchers noted that many comparisons were not direct, meaning they had to use math to guess the results. More research is needed to fully understand all the benefits and risks.

What this means for you:
Finerenone and SGLT2 inhibitors lower hospital visits and worsening heart failure, but some drugs have higher side effect risks.
Share
More on Heart Failure with Preserved Ejection Fraction